Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542993 · ClinicalTrials.gov registry record · Phase 2
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
A Phase 2 study, sponsored by Swedish Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT04542993 is a Phase 2 study that was terminated before completion, run by Swedish Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT04542993, a Phase 2 study, was terminated before completion, sponsored by Swedish Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
Interventions
- DIETARY_SUPPLEMENT Resveratrol
- DIETARY_SUPPLEMENT Zinc Picolinate
- DIETARY_SUPPLEMENT Zinc Picolinate Placebo
- DIETARY_SUPPLEMENT Resveratrol Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2021-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542993
The ClinicalTrials.gov registry entry for NCT04542993 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Resveratrol is the first listed.
NCT04542993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542993 about?
NCT04542993 is a clinical study titled "Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy". Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
What is the current status of trial NCT04542993?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-09-08. Estimated completion is 2021-02-05.
What interventions are being tested in trial NCT04542993?
The interventions under investigation include: Resveratrol (DIETARY_SUPPLEMENT), Zinc Picolinate (DIETARY_SUPPLEMENT), Zinc Picolinate Placebo (DIETARY_SUPPLEMENT), Resveratrol Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04542993?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.